Business Wire Industry News

Wednesday, April 23, 2025

Augurex Announces UKCA Authorization for SPINEstat™, Expanding Access to a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis to Great Britain

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AxialSpondyloarthritis--Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that SPINEstat™ has received UK Conformity Assessed (UKCA) marking by the Medicines and Healthcare products Regulatory Agency (MHRA), authorizing the blood test for clinical use and listing it as an in vitro diagnostic (IVD) in Great Britain. SPINEstat™ is a blood test that detects auto-antibodies to the 14-3-3eta protein and provides physicians with a new obj

Monday, April 21, 2025

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 121,500 common shares of the Company (the "Options"), with an effective grant date of April 21, 2025. The Options have an exercise price

Monday, April 21, 2025

Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC Patients1

SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals presented the first results from an ongoing Phase 3 trial in Japan assessing the efficacy and safety of nadofaragene firadenovec in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1).1 Nadofaragene firadenovec is the first and only intravesical non-replicating gene therapy approved by the U.S. Food an

Monday, April 21, 2025

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a strategic partnership with Osmind, a leading service provider advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. “Prepara

Monday, April 21, 2025

Anaergia and Capwatt Sign Binding Letter of Intent for Nine New Biogas Plants in Europe

TREVIGLIO, Italy & BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. (“Anaergia”, the “Company”, “us”, or “our”) (TSX:ANRG) (OTCQX:ANRGF), through its subsidiary, Anaergia S.r.l., entered into a binding Letter of Intent (“LOI”) with Capwatt Biomethane Unipessoal, Lda (“Capwatt”). Under the terms of this agreement, Anaergia is to design and build nine state-of-the-art facilities for biomethane production from agro-industry waste in Portugal, Spain, and Italy. Under the terms of this binding LO

Thursday, April 17, 2025

Covalon to Present at the Planet MicroCap Showcase: VEGAS on April 23, 2025

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that they will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 4:30 pm (Local Time -PST). Brent Ashton, Covalon’s CEO will review why Covalon is in the “sweet spot” in the microcap sector as an undervalued, cash rich, profitable healthcare compa

Wednesday, April 16, 2025

Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis

VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AxialSpondyloarthritis--Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that Health Canada has approved SPINEstat™, a first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), as a Class II medical device. By detecting auto-antibodies to the 14-3-3eta protein, SPINEstat™ provides an important new clinically validated and objective biomarker to aid in the early and accurate diagnosis of axSpA. AxSpA is a chron